ASSEMBLY BIOSCIENCES, INC. ASMB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-1.34
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $72.3M | -$6.1M | — | -$41.2M | $206.8M |
| 2024 | $28.5M | -$40.2M | — | -$51.1M | $33.4M |
| 2023 | $7.2M | -$61.2M | — | $22.5M | $41.1M |
| 2022 | $0 | -$93.1M | — | -$84.6M | $82.7M |
| 2021 | $6.3M | -$129.9M | — | -$96.5M | $168.9M |
| 2020 | $79.1M | -$62.2M | — | -$63.4M | $240.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Bjorkquist Jeanette M | PFO and PAO | 2026-06-17 | Sell | 29 | $23.25 |
| Gaggar Anuj | Chief Medical Officer | 2026-03-29 | Grant | 14,000 | — |
| White Nicole S | Chief Manufacturing Officer | 2026-03-29 | Grant | 14,000 | — |
| Bjorkquist Jeanette M | PFO and PAO | 2026-03-29 | Grant | 3,500 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.34 (distress)
- Working capital / assets 0.799
- Retained earnings / assets -3.23
- EBIT / assets -0.047
- Equity / liabilities 4.067
Source: SEC EDGAR filings · CIK 0001426800 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.